Ask yourself why you are consistently wildly at variance with these broker valuations.
Why? I'll give you an example.
Broker Wilsons forecasts $US35 million in DAYBUE net sales to Acadia in 2023. Not even close.
I guess they didn't use facts. They just pulled numbers out of the air. US$125,000??? Average orphan drug in USA is closer to double....
They could have used much more information about uptake starting with stable trial numbers rolling over, number of employed sales staff at Acadia, number on the register....
There will be people here who do more research than they do.
Just because its a brokers report doesn't make it gospel or completely valid.
Ann: Neuren and Acadia expand global partnership for trofinetide, page-131
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.100(0.80%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.44 | $12.73 | $12.13 | $11.07M | 885.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1215 | $12.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.54 | 804 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |